Combination treatment of the oral CHK1 inhibitor, SRA737 and low dose gemcitabine, enhances the effect of PD-L1 blockade by modulating the immune microenvironment in small cell lung cancer.

Despite the enthusiasm surrounding cancer immunotherapy, most small cell lung cancer (SCLC) patients show very modest response to immune checkpoint inhibitor monotherapy treatment. There is therefore growing interest in combining immune checkpoint blockade (ICB) with chemotherapy and other treatment...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Thorac Oncol
Main Authors: Sen, Triparna, Della Corte, Carminia M., Milutinovic, Snezana, Cardnell, Robert J, Diao, Lixia, Ramkumar, Kavya, Gay, Carl M., Stewart, C Allison, Fan, Youhong, Shen, Li, Hansen, Ryan J., Strouse, Bryan, Hedrick, Michael P., Hassig, Christian A., Heymach, John V., Wang, Jing, Byers, Lauren A
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7141083/
https://ncbi.nlm.nih.gov/pubmed/31470128
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2019.08.009
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados